ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 8, 2018
The Turnaround at Novartis Has Begun
Image Source: Novartis. We believe Novartis is poised to accelerate from the patent cliff caused by the loss of protection of Gleevec, its former top-selling product. The company has a stellar dividend growth history, and the market is anticipating a turnaround once it anniversaries the patent cliff.
Feb 7, 2018
Hasbro, Boeing Pop as Market Bounces Back
Image Source: US Missile Defense Agency. June 22, 2014 - The Missile Defense Agency's Flight Test 06b Ground-Based Interceptor launches from Vandenberg Air Force Base, Calif. on June 22, 2014. The markets have finally been getting the volatility that we’ve all been waiting for, and we don’t like the idea that the market is now trading more like a cryptocurrency. Granted, it’s important to stay focused over a long-term time horizon, which irons out the ups and downs, but there’s just something about 1,000+ daily swings on the Dow Jones Industrial Average that really doesn’t sit well with us, regardless of what that implies with respect to the percentage change. Can you imagine -- All of this over just a couple basis point increase in the 10-year and one very, very small ETF losing most of its value? What if something truly material happens? This market is fragile.
Feb 6, 2018
Newsletter Portfolio Idea GM Powers Higher, Markets Calm Down…a Bit
The US markets still faced quite a bit of volatility during the trading session February 6, but it wasn’t anything compared to the bloodbath from Groundhog Day and the subsequent Monday. We can only hope that the worst has passed, but it probably hasn’t.
Feb 5, 2018
Dropping Coverage of the Homebuilders Industry
Image Source: ArmchairBuilder.com. We are dropping coverage of the homebuilders industry to allocate resources elsewhere.
Jan 31, 2018
Boeing!
Image shown: Boeing's shares have been rocketing higher of late! We couldn’t be more pleased with how one of our best ideas for consideration has performed: Boeing!
Jan 29, 2018
The 10-year US Treasury Yield, Trump and Trade and More
We continue to pay very close attention to the benchmark 10-year Treasury yield as it has implications on borrowing costs and discount rates across valuation methodologies.
Jan 29, 2018
Dropping Coverage of a Few Clothing Retailers
Valuentum is dropping coverage of a few clothing retailers to focus resources elsewhere.
Jan 29, 2018
Dropping Coverage of the Book Publishing Industry
Image shown: The first seven annual volumes of Valuentum's Best Ideas Newsletter. Valuentum is dropping coverage of the book publishing industry to focus resources elsewhere.
Jan 28, 2018
The US Dollar, GDP Expansion, and Earnings
Investors wouldn’t think news flow is that robust given that stock market volatility in recent months has been practically nil, but news is coming in fast. Let’s check up on the performance of the US dollar, the rate of GDP growth as well as key companies reporting fourth-quarter earnings. Intel’s quarterly report was fantastic, for one!
Jan 28, 2018
Our Overview on Merck in Light of Recent Clinical Events
Image Source: Merck. Clinical data reads can have an outsize impact on the fortunes of the research-based pharma industry, irrespective of the size of the organization. We came away very impressed with the recent release from Merck and felt a timely overview of the various pharmaceutical products developed by the company would be of value to readers.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.